

5

Abstract of Disclosure

The present invention relates to the use of energy kinase modulators for treating or preventing energy related disorders consisting of neurodegenerative disorder, insulin dependent diabetes mellitus and its related disorders, obesity, mitochondrial related diseases and viral infections in a patient experiencing said disorder. The modulators are compounds which can modulate (1) the activity of the enzyme and or its oligomerisation state (2) the nucleotide pool regulated by this kinase (3) the location of the enzyme in the mitochondria or its ability to interact with other mitochondrial components (4) the energy transmitting function of the enzyme and its ability to connect the cytosol and mitochondrial communication and/or(5) flux in and out of the mitochondria.

664030" 664030"